Iksabepilon

Iksabepilon
Nama sistematis (IUPAC)
	(1R,5S,6S,7R,10S,14S,16S)-6,10-dihidroksi-1,5,7,; 9,9-pentametil-14-[(E)-1-(2-metil-1,3-tiazol-; 4-il)prop-1-en-2-il]-17-oksa-13-azabisiklo[14.1.0]; heptadekana-8,12-diona
Data klinis
Nama dagang	Ixempra
AHFS/Drugs.com	monograph
MedlinePlus	a608042
Data lisensi	US Daily Med:pranala
Kat. kehamilan	D(US)
Status hukum	℞-only (US)
Rute	Intravena
Data farmakokinetik
Bioavailabilitas	N/A
Ikatan protein	67 – 77%
Metabolisme	Secara luas di hati, dimediasi CYP3A4
Waktu paruh	52 jam
Ekskresi	Tinja (kebanyakan) dan ginjal
Pengenal
Nomor CAS	219989-84-1
Kode ATC	L01DC04
PubChem	CID 6445540
Ligan IUPHAR	6824
DrugBank	DB04845
ChemSpider	20145579
UNII	K27005NP0A
KEGG	D04645
ChEMBL	CHEMBL1201752
Sinonim	Azaepotilon B
Data kimia
Rumus	C27H42N2O5S
SMILES	eMolecules & PubChem
	InChI InChI=1S/C27H42N2O5S/c1-15-9-8-10-27(7)22(34-27)12-20(16(2)11-19-14-35-18(4)28-19)29-23(31)13-21(30)26(5,6)25(33)17(3)24(15)32/h11,14-15,17,20-22,24,30,32H,8-10,12-13H2,1-7H3,(H,29,31)/b16-11+/t15-,17+,20-,21-,22-,24-,27+/m0/s1 ; Key:FABUFPQFXZVHFB-PVYNADRNSA-N ;

Iksabepilon (INN; juga dikenal sebagai azaepotilon B, nama kode BMS-247550) adalah obat yang dikembangkan oleh Bristol Myers Squibb sebagai obat kemoterapi untuk kanker.^[1]

Sejarah

Iksabepilon adalah analog semi-sintetik dari epotilon B, senyawa kimia alami yang diproduksi oleh bakteri Sorangium cellulosum.^[2] Perbedaan struktural antara Epotilon B dan iksabepilon hanya terdiri dari substitusi oksigen-nitrogen satu atom yang mengubah ester menjadi amida. Epotilon B sendiri tidak dapat dikembangkan sebagai obat farmasi karena stabilitas metabolik dan farmakokinetikanya yang buruk. Iksabepilon dirancang melalui kimia medisinal untuk meningkatkan sifat-sifat ini.^[3]

Farmakologi

Seperti paklitaksel, iksabepilon bertindak untuk menstabilkan mikrotubulus.^[4]^[5]^[6] Obat ini sangat kuat, mampu merusak sel kanker dalam konsentrasi yang sangat rendah, dan mempertahankan aktivitas dalam kasus di mana sel tumor tidak sensitif terhadap obat jenis taksana.^[7]

Persetujuan

Kegunaan klinis

Referensi

^ "More information on cancer drugs". www.cancer.org.
^ Goodin S (May 2008). "Novel cytotoxic agents: epothilones". American Journal of Health-System Pharmacy. 65 (10 Suppl 3): S10–S15. doi:10.2146/ajhp080089. PMID 18463327.
^ Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R, Vite G (December 2008). "Preclinical discovery of ixabepilone, a highly active antineoplastic agent". Cancer Chemotherapy and Pharmacology. 63 (1): 157–166. doi:10.1007/s00280-008-0724-8  . PMID 18347795.
^ Lopus M, Smiyun G, Miller H, Oroudjev E, Wilson L, Jordan MA (November 2015). "Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype". Cancer Chemotherapy and Pharmacology. 76 (5): 1013–1024. doi:10.1007/s00280-015-2863-z. PMID 26416565.
^ Denduluri N, Swain SM (March 2008). "Ixabepilone for the treatment of solid tumors: a review of clinical data". Expert Opinion on Investigational Drugs. 17 (3): 423–435. doi:10.1517/13543784.17.3.423. PMID 18321240.
^ Goodin S (November 2008). "Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer". American Journal of Health-System Pharmacy. 65 (21): 2017–2026. doi:10.2146/ajhp070628. PMID 18945860.
^ Vulfovich M, Rocha-Lima C (June 2008). "Novel advances in pancreatic cancer treatment". Expert Review of Anticancer Therapy. 8 (6): 993–1002. doi:10.1586/14737140.8.6.993. PMID 18533808.

Pranala luar

[1] "More information on cancer drugs". www.cancer.org.

[pmid18463327-2] Goodin S (May 2008). "Novel cytotoxic agents: epothilones". American Journal of Health-System Pharmacy. 65 (10 Suppl 3): S10–S15. doi:10.2146/ajhp080089. PMID 18463327.

[pmid18347795-3] Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R, Vite G (December 2008). "Preclinical discovery of ixabepilone, a highly active antineoplastic agent". Cancer Chemotherapy and Pharmacology. 63 (1): 157–166. doi:10.1007/s00280-008-0724-8  . PMID 18347795.

[4] Lopus M, Smiyun G, Miller H, Oroudjev E, Wilson L, Jordan MA (November 2015). "Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype". Cancer Chemotherapy and Pharmacology. 76 (5): 1013–1024. doi:10.1007/s00280-015-2863-z. PMID 26416565.

[pmid18321240-5] Denduluri N, Swain SM (March 2008). "Ixabepilone for the treatment of solid tumors: a review of clinical data". Expert Opinion on Investigational Drugs. 17 (3): 423–435. doi:10.1517/13543784.17.3.423. PMID 18321240.

[pmid18945860-6] Goodin S (November 2008). "Ixabepilone: a novel microtubule-stabilizing agent for the treatment of metastatic breast cancer". American Journal of Health-System Pharmacy. 65 (21): 2017–2026. doi:10.2146/ajhp070628. PMID 18945860.

[pancreas-7] Vulfovich M, Rocha-Lima C (June 2008). "Novel advances in pancreatic cancer treatment". Expert Review of Anticancer Therapy. 8 (6): 993–1002. doi:10.1586/14737140.8.6.993. PMID 18533808.

[1]

[2]

[3]

[4]

[5]

[6]

[7]